繁
简
Market+ (iPhone)
Market+ (Android)
Mobile Site
US STOCKS
FUNDS
FX & CRYPTO
SH/SZ-HK
HK STOCKS
 
 
 
 
 
 
Quote Service
Market
Market
Quotes
Quotes
Analysis
Analysis
Commentary
Commentary
Warrants&CBBCs
Warrants&CBBCs
Warrants&CBBCs Overview
Warrants
CBBCs
ETF
ETF
MPF
MPF
Education
Members
Members
About Us
About Us

IPO Plus - IPO

To-be Listed (Grey Market Trading Session: 14:15-16:30)
Name▼
/
Code▲
 Industry Listing Price Lot Size Entry Fee Phillip Grey Market Futu (HK) Grey Market
Biren Technology
06082.HK
Grey Market Today
 Advanced hardware and software Pending 200 3,959.54
-
-
 Detail Quote
Last update:
Name▼
/
Code▼
 Industry Offer Price Lot Size Entry Fee Closing Date
Grey Market Date▼
Listing Date▲
Knowledge Atlas
02513.HK		 Next-generation information technology 116.2 100 11,737.19 2026/01/05 2026/01/07 2026/01/08
Edge Medical-B
02675.HK		 Biotechnology - Medical Devices 43.24 100 4,367.61 2026/01/05 2026/01/07 2026/01/08
Iluvatar CoreX
09903.HK		 Semiconductors & Semiconductor Equipment 144.6 100 14,605.83 2026/01/05 2026/01/07 2026/01/08
MiniMax-WP
00100.HK		 Next-generation information technology 151-165 20 3,333.28 2026/01/06 2026/01/08 2026/01/09
Jinxun Resources
03636.HK		 Diversified Metals & Minerals 30 200 6,060.51 2026/01/06 2026/01/08 2026/01/09
Ribo Life-B
06938.HK		 Biotechnology - Pharmaceuticals 57.97 200 11,710.93 2026/01/06 2026/01/08 2026/01/09
OmniVision
00501.HK		 Semiconductors & Semiconductor Equipment N/A 100 10,585.69 2026/01/07 2026/01/09 2026/01/12
HX Coldchain
01641.HK		 Packaged Foods 12.26 500 6,191.83 2026/01/08 2026/01/12 2026/01/13
GigaDevice
03986.HK		 Semiconductors & Semiconductor Equipment 132-162 100 16,363.38 2026/01/08 2026/01/12 2026/01/13
BBSB International
08610.HK		 Construction & Engineering 0.6-0.7 4,000 2,828.24 2026/01/08 2026/01/12 2026/01/13
Edge Medical-B (02675.HK)
Summary
Founded in 2017, we are an advanced surgical robot company in the medical device industry, dedicated to designing, developing and manufacturing surgical robots. We have a pipeline of three products and product candidates covering various models at different development stages to capture the market potential in surgical robots, including multi-port endoscopic surgical robots and single-port endoscopic surgical robots for minimally invasive surgery (“MIS”), as well as natural orifice surgical robots for non invasive surgery. Currently, our product portfolio comprises two self-developed Core Products: Edge Multi-Port Endoscopic Surgical Robot and Edge Single-Port Endoscopic Surgical Robot. Our product portfolio also includes Edge Bronchoscope Robot, which is not a Core Product. Edge Multi-Port Endoscopic Surgical Robot is a robot-assisted device that is applied to perform MIS, using robotic, imaging and digital technologies, covering applications in urologic, gynecologic, general and thoracic surgery. Edge Single-Port Endoscopic Surgical Robot is a robot assisted device that is applied to perform MIS through a single small incision or natural orifice, covering applications in urologic, gynecologic and general surgery.

OUR CORE PRODUCTS ARE EDGE MULTI-PORT ENDOSCOPIC SURGICAL ROBOT AND SINGLE-PORT ENDOSCIPIC SURGICAL ROBOT. WE MAY NOT BE ABLE TO SUCCESSFULLY MARKET OUR CORE PRODUCTS IN OVERSEAS MARKETS AS PLANNED, OR SUCCESSFULLY DEVELOP OR MARKET THE EXPANSION OF SURGICAL APPLICATIONS (E.G., UROLOGIC, GYNECOLOGIC, GENERAL AND THORACIC TELESURGERIES, AS WELL AS PEDIATRIC, CARDIAC AND OTORHINOLARYNGOLOGY (ENT), HEAD AND NECK SURGERIES) OF OUR CORE PRODUCTS AND OTHER PRODUCT CANDIDATES IN CHINA OR IN OVERSEAS MARKETS (E.G., JAPAN AND KOREA). EXPANSIONS OF CERTAIN SURGICAL APPLICATIONS ARE IN THE EARLY STAGE OF CLINICAL DEVELOPMENT IN WHICH WE MAY CONTINUE TO INCUR SUBSTANTIAL COSTS AND EXPENSES IN RELATION TO FURTHER RESEARCH AND DEVELOPMENT ACTIVITIES FOR OUR CORE PRODUCTS.

We are the first in China and the second in the world that had received registration approvals of all of multi-port endoscopic surgical robots, single-port endoscopic surgical robots and natural orifice surgical robots, according to Frost & Sullivan. We received the initial registration approval from the NMPA for our Edge Multi-Port Endoscopic Surgical Robot, Edge Single-Port Endoscopic Surgical Robot and Edge Bronchoscope Robot in December 2022, November 2023 and January 2025, respectively.

MIS has become an increasingly prevalent and preferred surgical approach mainly due to its clinical benefits such as less invasiveness, minimized surgical wounds, faster recovery and fewer postoperative complications. As new technologies in surgical robotics are emerging, robot-assisted MIS has become the trend given its superior treatment results compared with open surgery and conventional MIS. Robot-assisted MIS not only brings patients all the benefits of conventional MIS, but also significantly extends a surgeon’s capabilities by providing three-dimensional high-definition (“3DHD”) visualization of the anatomy, optimizing instrument movements, filtering out tremors inherent in human hands and reducing surgeons’ fatigue. We have witnessed market opportunities and unmet clinical needs in China’s surgical robot market and are positioned to capture these opportunities.

Edge Multi-Port Endoscopic Surgical Robot, our Core Product, is a robot-assisted device that is applied to perform MIS using robotic, imaging and digital technologies. With its assistance, trained surgeons can easily manipulate the robotic arms that are positioned inside the patient through small incisions to perform surgery while seated comfortably at a console viewing a high resolution 3D image of the surgical field. In December 2022, we received the registration approval from the NMPA for MP1000, its first model, for application in urologic surgery. In August 2023, we received the registration approval from the NMPA for expansion of MP1000’s clinical application in gynecology, general surgery and thoracic surgery. MP1000 is the first domestically-developed endoscopic surgical robot approved by the NMPA for applications in multiple surgical specialties, according to Frost & Sullivan. In October 2023 and July 2024, the NMPA approved our registration modification for an updated version of MP1000, also known as MP1000 Plus, and MP2000 series, the second generation of our MP1000, respectively. We have been expanding our overseas registration and sales since 2025.

In March 2025, we obtained the CE Marking of MP1000 in the EU. We started to commercialize Edge Multi-Port Endoscopic Surgical Robot in China in December 2022. We sold 20 units of Edge Multi-Port Endoscopic Surgical Robot in China in 2024, ranking first among domestic surgical robot manufacturers, according to Frost & Sullivan. In terms of contractual sales volume, we have entered into agreements for sales of 31 units of Edge Multi-Port Endoscopic Surgical Robot in the six months ended June 30, 2025.

Edge Single-Port Endoscopic Surgical Robot, our Core Product, is a robot-assisted device that is applied to perform MIS through a single small incision or natural orifice, and is complementary to our Edge Multi-Port Endoscopic Surgical Robot. All instruments are incorporated in a single robotic arm that operates through a cannula. In November 2023, we received the registration approval from the NMPA for SP1000, its first model, for application in gynecology. In October 2024, we received the registration approval from the NMPA for expansion of SP1000’s clinical application in urologic surgery and general surgery. SP1000 is the first (but currently not the only) domestically-developed single-port endoscopic surgical robot approved by the NMPA covering three or more major surgical specialties, according to Frost & Sullivan. We started to commercialize Edge Single-Port Endoscopic Surgical Robot in China in 2024. In addition, in October 2025, we obtained the CE Marking of SP1000 in the EU.

Besides our Core Products, in January 2025, we also received the registration approval from the NMPA for Edge Bronchoscope Robot, a natural orifice surgical robot for natural orifice transluminal endoscopic surgery, or NOTES. It is designed for diagnostic and therapeutic bronchoscopic procedures by navigating the lung periphery with a flexible robotic endoscope. We started to commercialize our Edge Bronchoscope Robot in China in September 2025.



Source: Edge Medical-B (02675) Prospectus (IPO Date : 2025/12/30)
Listing Market MAIN
Industry Biotechnology - Medical Devices
Background H Shares
Major Business Area China
Corporate Information
Substantial Shareholders Wang Jianchen (Total share: 43.31%); (H share: 37.40%)
Directors Wang Jianchen (Chairman and Executive Director)
Gao Yuanqian (Executive Director)
Wu Mengyuan (Executive Director)
Chen Gang (Non-Executive Director)
Qiu Xiang (Non-Executive Director)
Sheng Li (Non-Executive Director)
Lau Ying Kit (Independent Non-Executive Director)
Yang Fan (Independent Non-Executive Director)
Zhang Guoguang (Independent Non-Executive Director)
Company Secretary Li Kin Wai
Wu Mengyuan
Principal Bankers Bank Of China Bank
China Merchants Bank
Solicitors Jingtian & Gongcheng
Cleary Gottlieb Steen & Hamilton (Hong Kong)
Auditors KPMG
Registered Office Room 1918, 19/F., Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong
Share Registrars Tricor Investor Services Ltd. [Tel: (852) 2980-1333]
Share Registrars Tel No (852) 2980-1333
Internet Address https://www.edgemed.cn
Email Address contact@edgemed.cn
Tel No (86 400) 860-9000
Fax No
 
SITEMAP
AASTOCKS.com
 
 
Members
 
About Us
Market
Quotes
 
Analysis
News & Research
 
Commentary
 
Warrants&CBBCs
 
Warrants
 
CBBCs
 
US Stocks
Forex
 
Fund
 
MPF
Email: support@aastocks.com
AASTOCKS.COM LIMITED (阿斯達克網絡信息有限公司) All rights reserved.
Disclaimer
You expressly agree that the use of this app/website is at your sole risk.

AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd, Nasdaq, Inc., their respective holding companies and/or any subsidiaries of such holding companies, their Sources and/or other third party data provider(s) endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co.Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) make any express or implied offers, representations or warranties (including, without limitation, any warranty or merchantability or fitness for a particular purpose or use) regarding the Information.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) will be liable to any Subscriber or any other party for any interruption, inaccuracy, error, or omission, regardless of cause, in the Information or for any damages (whether direct or indirect, consequential, punitive, or exemplary) resulting from its use by any party.

AASTOCKS.com Limited shall not be liable for any failure or delay in performance of its obligations under this Disclaimer because of circumstances beyond its reasonable control, including but without limitation, acts of God, typhoons, rainstorms, other natural disasters, government restrictions, strikes, wars, virus outbreak, network failures or telecommunications failures.

Morningstar Disclaimer: Copyright © 2020 Morningstar, Inc. All Rights Reserved. The information, data, analyses and opinions ("Information") contained herein: (1) include the proprietary information of Morningstar and Morningstar’s third party licensors; (2) may not be copied or redistributed except as specifically authorised; (3) do not constitute investment advice; (4) are provided solely for informational purposes; and (5) are not warranted to be complete, accurate or timely. Morningstar is not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

The information and contents contained in this app/website are based on the analyses and interpretations of publicly available information obtained from sources believed to be reliable. Such analyses and information have not been independently verified and AASTOCKS.com Limited makes no guarantees to their accuracy, completeness, timeliness or correctness.

The information, financial market data, quotes, charts, statistics, exchange rate, news, research, analysis, buy and sell ratings, Education Center and other information on this app/website should be used as references only at your own discretion. Prior to the execution of a security or any other trade based upon the Information, you are advised to consult independent professional advice to verify pricing information or to obtain more detailed market information. AASTOCKS.com Limited is not soliciting any subscriber or app/website visitor to execute any trade. Any trades executed following the said information, commentaries and/or buy/sell ratings on this app/website are taken at your own risk for your own account.

AASTOCKS.com Limited provides the information and services on an "AS IS" basis. The information and contents on this app/website are subject to change without notice. AASTOCKS.com Limited reserves the right, in its sole discretion but without any obligation, to make improvements to, or correct any error or omissions in any portion of this app/website at any time.

The subscriber or app/website visitor agrees not to reproduce, retransmit, disseminate, distribute, broadcast, publish, circulate, sell or commercially exploit the information and contents on this app/website in any manner without the express written consent of AASTOCKS.com Limited.

Investment involves risk. You may make use of the Education Center of this website for academic reference purposes at your own discretion. AASTOCKS.com Limited cannot and does not give any assurance that the present or future buy/sell commentaries and signals on this app/website will be profitable. AASTOCKS.com Limited cannot guarantee, and the subscriber or app/website visitor should not assume, that the future performance will equal past performance.

AASTOCKS.com Limited may point to other sites that may be of interest to the subscriber or app/website visitor but for which AASTOCKS.com Limited has no responsibility and only provides this as a service to the subscriber or app/website visitor.

AASTOCKS.com Limited does not represent or endorse the accuracy or reliability of any information, advertisements or contents contained on, distributed through, or linked, downloaded or accessed from any of the services on this app/website. AASTOCKS.com Limited cannot and does not guarantee the quality or reliability of any products or information purchased or obtained by you as a result of an advertisement or any other information displayed on this app/website.

AATV is a video platform owned by AASTOCKS.com Limited.

You acknowledge that: (i) AATV is provided for information purposes only and, in particular, is not intended for trading purposes; (ii) AATV does not and none of the information contained in its program constitutes a solicitation, offer, opinion, or recommendation by us to buy or sell any security, or to provide legal, tax, accounting, or investment advice or services whether or not regarding the profitability or suitability of any security or investment; and (iii) AATV is not intended for use by, or distribution to, any person or entity in any jurisdiction or country where such use or distribution would be contrary to law or regulation.

The financial analysis or opinion expressed in the AATV programs is for reference and discussion only, and does not represent AASTOCKS.com Limited. Investors must make their own investment decisions based on their own investment objectives and financial situation. AASTOCKS.com Limited shall not, directly or indirectly, be liable, in any way, to you or any other person for any: (i) inaccuracies or errors in or omissions from AATV including, but not limited to, quotes and financial data; (ii) delays, errors, or interruptions in the transmission or delivery of AATV; or (iii) loss or damage arising therefrom or occasioned thereby, or by any reason of nonperformance.

AASTOCKS.com Limited reserves the right to change this Disclaimer at any time by posting changes online at this app/website. You are responsible for reviewing regularly information posted therein to obtain timely notice of such changes. Your continued use of this app / website after changes are posted constitutes your acceptance of this Agreement as modified by the posted changes.

The disclaimer herein shall be governed by the law of the Hong Kong Special Administrative Region of the People's Republic of China ("Hong Kong") and you agree to submit to the exclusive jurisdiction of the Hong Kong courts.

In the event of any discrepancy between the Chinese and English versions, the English version shall prevail.

Last updated on 6 January 2023.